All In Biotech

Drug Trial Radar · NCT00003907

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial

Last checked: Nov 20, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Dec 15, 1999

Primary completion

May 2011

Study completion Aug 2012

Sponsor

Lead sponsor
Eastern Cooperative Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 9, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.

Conditions

  • Liver Cancer
  • Metastatic Cancer

Interventions

  • cisplatinDrug

    Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

  • doxorubicinDrug

    Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

  • mitomycinDrug

    Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

  • embolizationProcedure

    Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to ProgressionTime frame: Assessed every 3 months for 2 years, then every 6 months for 3 year.

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Front Range Cancer Specialists

    Fort Collins, Colorado

  • Baptist Cancer Institute - Jacksonville

    Jacksonville, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Veterans Affairs Medical Center - Atlanta (Decatur)

    Decatur, Georgia

  • Rush-Copley Cancer Care Center

    Aurora, Illinois

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois

  • Hematology and Oncology Associates

    Chicago, Illinois

  • Veterans Affairs Medical Center - Lakeside Chicago

    Chicago, Illinois

  • Mercy Hospital and Medical Center

    Chicago, Illinois

  • Swedish Covenant Hospital

    Chicago, Illinois

  • Hinsdale Hematology Oncology Associates

    Hinsdale, Illinois

  • Midwest Center for Hematology/Oncology

    Joliet, Illinois

  • Joliet Oncology-Hematology Associates, Limited - West

    Joliet, Illinois

  • North Shore Oncology and Hematology Associates, Limited - Libertyville

    Libertyville, Illinois

  • Hematology Oncology Associates - Skokie

    Skokie, Illinois

  • Hematology/Oncology of the North Shore at Gross Point Medical Center

    Skokie, Illinois

  • Carle Cancer Center at Carle Foundation Hospital

    Urbana, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • Saint Anthony Memorial Health Centers

    Michigan City, Indiana

  • Mercy Capitol Hospital

    Des Moines, Iowa

  • CCOP - Iowa Oncology Research Association

    Des Moines, Iowa

  • John Stoddard Cancer Center at Iowa Methodist Medical Center

    Des Moines, Iowa

  • Medical Oncology and Hematology Associates at John Stoddard Cancer Center

    Des Moines, Iowa

  • Medical Oncology and Hematology Associates at Mercy Cancer Center

    Des Moines, Iowa

  • Mercy Cancer Center at Mercy Medical Center - Des Moines

    Des Moines, Iowa

  • John Stoddard Cancer Center at Iowa Lutheran Hospital

    Des Moines, Iowa

  • Medical Oncology and Hematology Associates - West Des Moines

    West Des Moines, Iowa

  • Borgess Medical Center

    Kalamazoo, Michigan

  • West Michigan Cancer Center

    Kalamazoo, Michigan

  • Bronson Methodist Hospital

    Kalamazoo, Michigan

  • Carol G. Simon Cancer Center at Morristown Memorial Hospital

    Morristown, New Jersey

  • Somerset Medical Center

    Somerville, New Jersey

  • Overlook Hospital

    Summit, New Jersey

  • Case Comprehensive Cancer Center

    Cleveland, Ohio

  • St. Rita's Medical Center

    Lima, Ohio

  • Fox Chase Cancer Center - Philadelphia

    Philadelphia, Pennsylvania

  • Albert Einstein Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.